Quanterix Faces Financial Challenges Amid New Bylaws Adoption and Acquisition of Akoya Biosciences

Quanterix reported a 29% revenue decrease and net loss of $30 million in Q2 2025. Despite this, the company highlighted growth in Alzheimer's Diagnostics revenues and strategic actions for long-term growth. The Board of Directors adopted new bylaws for majority voting in director elections. Quanterix expects to achieve cash flow breakeven in 2026 and exit 2025 with $120 million in cash. The stock has a Hold rating with an $8.00 price target.

Quanterix Corporation (NASDAQ: QTRX), a leader in ultra-sensitive biomarker detection, announced its financial results for the second quarter ended June 30, 2025. The company reported a 29% decrease in revenue, totaling $24.5 million, compared to $34.4 million in the prior year. Despite the revenue decline, Quanterix highlighted significant growth in Alzheimer's Diagnostics revenues and strategic actions to position the business for long-term growth.

The company's net loss for the quarter was $30.0 million, compared to a net loss of $7.4 million in the prior year. The GAAP gross margin decreased to 46.2% from 64.7% in the prior year, while the adjusted gross margin (non-GAAP) was 41.8%, down from 58.6% in the prior year. Quanterix ended the quarter with $263.8 million in cash, cash equivalents, marketable securities, and restricted cash, representing a use of cash of approximately $5.7 million.

Quanterix's strategic initiatives included the completion of the acquisition of Akoya Biosciences, the launch of new Alzheimer’s research assays, and the approval of the UltraDx Plasma pTau-217 Assay Kit in China. The company expects to report revenues in a range of $130 to $135 million for 2025, including approximately two quarters of performance from Akoya. On a pro forma basis, Quanterix expects to generate between $165 and $170 million in revenue for 2025.

The Board of Directors adopted new bylaws for majority voting in director elections. Quanterix expects to achieve cash flow breakeven in 2026 and exit 2025 with approximately $120 million in cash and cash equivalents. The stock has a Hold rating with an $8.00 price target.

References:
[1] https://finance.yahoo.com/news/quanterix-releases-financial-results-second-200600409.html